Novel approaches for preventing or limiting events in diabetic patients (naples-diabetes) trial: A randomized comparison of 3 drug-eluting stents in diabetic patients

Circulation: Cardiovascular Interventions

Volumn 4, Issue 2, 2011, Pages 121-129

  Briguori, Carlo ^a   Airoldi, Flavio ^b   Visconti, Gabriella ^a   Focaccio, Amelia ^a   Caiazzo, Gianluca ^a   Golia, Bruno ^a   Biondi Zoccai, Giuseppe ^c   Ricciardelli, Bruno ^a   Condorelli, Gerolama ^d  

^a Clinica Mediterranea   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Diabetes mellitus; Drug eluting stent; Outcome

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENDEAVOR (DRUG); EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; HEMOGLOBIN A1C; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; MIDDLE AGED; MORTALITY; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; SIROLIMUS;

EID: 80051761566     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.959924     Document Type: Article

References (35)

1. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, Fernandez C, Fernandez-Aviles F, Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (diabetes) trial. Circulation. 2005;112:2175-2183. (Pubitemid 41475813)
2. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a sirius (sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-2278. (Pubitemid 38678518)
3. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW. Outcomes with the polymer-based paclitaxel-eluting taxus stent in patients with diabetes mellitus: the taxus-iv trial. J Am Coll Cardiol. 2005;45:1172-1179. (Pubitemid 40523133)
4. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Mauri L. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008;118:2277-2285.
5. Zhang F, Dong L, Ge J. Meta-analysis of five randomized clinical trials comparing sirolimus-versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol. 2010;105:64-68.
6. Billinger M, Beutler J, Taghetchian KR, Remondino A, Wenaweser P, Cook S, Togni M, Seiler C, Stettler C, Eberli FR, Luscher TF, Wandel S, Juni P, Meier B, Windecker S. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J. 2008;29:718-725. (Pubitemid 351431021)
7. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus-and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J. 2007;28:26-32. (Pubitemid 46134954)
8. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-670. (Pubitemid 41175674)
9. Wolf WM, Vlachos HA, Marroquin OC, Lee JS, Smith C, Anderson WD, Schindler JT, Holper EM, Abbott JD, Williams DO, Laskey WK, Kip KE, Kelsey SF, Mulukutla SR. Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the national heart, lung, and blood institute dynamic registry. Circ Cardiovasc Interv. 2010;3:42-49.
10. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989-997. (Pubitemid 46376799)
11. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the Endeavor II trial. Circulation. 2006;114: 798-806. (Pubitemid 44268230)
12. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS Jr, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM III, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE. A randomized comparison of the endeavor zotarolimus-eluting stent versus the taxus paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the Endeavor IV trial. J Am Coll Cardiol. 2010;55:543-554.
13. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004; 27(Suppl 1):S5-S10.
14. Briguori C, Condorelli G, Airoldi F, Manganelli F, Violante A, Focaccio A, Ricciardelli B, Colombo A. Impact of microvascular complications on outcome after coronary stent implantations in patients with diabetes. J Am Coll Cardiol. 2005;45:464-466. (Pubitemid 40186803)
15. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie house classification: ETDRs report number 10: Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786-806.
16. K/doqi clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
17. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961-972.
18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. (Pubitemid 46685903)
19. Briguori C, Colombo A, Airoldi F, Focaccio A, Iakovou I, Chieffo A, Michev I, Montorfano M, Bonizzoni E, Ricciardelli B, Condorelli G. Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Am Heart J. 2005;150:807-813. (Pubitemid 41396519)
20. Hernandez AV, Steyerberg EW, Habbema JD. Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements. J Clin Epidemiol. 2004;57:454-460. (Pubitemid 38758048)
21. Boyden TF, Nallamothu BK, Moscucci M, Chan PS, Grossman PM, Tsai TT, Chetcuti SJ, Bates ER, Gurm HS. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol. 2007;99:1399-1402. (Pubitemid 46686640)
22. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, Sangiorgio P, Tarantino F, Geraci G, Castriota F, Tondi S, Saia F, Cooke RM, Guastaroba P, Grilli R, Marzocchi A, Maresta A. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation. 2008;117:923-930. (Pubitemid 351272590)
23. Stenestrand U, James SK, Lindback J, Frobert O, Carlsson J, Schersten F, Nilsson T, Lagerqvist B. Safety and efficacy of drug-eluting vs bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2010;31:177-186.
24. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357: 1393-1402. (Pubitemid 47541971)
25. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, Stone GW. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol. 2008;51:708-715. (Pubitemid 351227416)
26. Carter AJ. Tor of the cell cycle: are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv. 2004;61:233-236. (Pubitemid 38160625)
27. Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Clinical and angiographic outcomes in diabetics from the endeavor IV trial: randomized comparison of zotarolimus-and paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol Cardiovasc Interv. 2009;2:967-976.
28. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
29. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:1030-1039. (Pubitemid 46376803)
30. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (Clin Res Ed). 2008;337:a1331.
31. Rivero F, Moreno R, Barreales L, Galeote G, Sanchez-Recalde A, Calvo L, Jimenez-Valero S, Villate A, Vanegas M, Lopez-Sendon JL. Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug-eluting stents. EuroIntervention. 2008;4:124-132.
32. Briguori C, Condorelli G, Airoldi F, Focaccio A, D'Andrea D, Cannavale M, Abarghouei AA, Giordano S, De Vivo F, Ricciardelli B, Colombo A. Comparison of coronary drug-eluting stents versus coronary artery bypass grafting in patients with diabetes mellitus. Am J Cardiol. 2007;99:779-784. (Pubitemid 46365594)
33. Ohno T, Takamoto S, Motomura N, Ono M, Ando J, Morita T, Fujita H, Hirata Y, Nagai R, Shigeeda T, Hirose A. Coronary artery bypass grafting versus coronary implantation of sirolimus-eluting stents in patients with diabetic retinopathy. Ann Thorac Surg. 2007;84:1474-1478. (Pubitemid 47588145)
34. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
35. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559. (Pubitemid 351831356)